Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study
Abstract Background The purpose of this study is to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) versus chemotherapy alone for patients with stage IV esophageal squamous cell carcinoma (ESCC). Methods Eligible patients were retrospectively enrolled at the authors’s institut...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-11-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13014-018-1183-y |
| _version_ | 1819013575969079296 |
|---|---|
| author | Jiahua Lyu Tao Li Qifeng Wang Fang Li Peng Diao Li Liu Churong Li Jinyi Lang |
| author_facet | Jiahua Lyu Tao Li Qifeng Wang Fang Li Peng Diao Li Liu Churong Li Jinyi Lang |
| author_sort | Jiahua Lyu |
| collection | DOAJ |
| description | Abstract Background The purpose of this study is to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) versus chemotherapy alone for patients with stage IV esophageal squamous cell carcinoma (ESCC). Methods Eligible patients were retrospectively enrolled at the authors’s institution from January 2010 to October 2015. Of the 141 patients enrolled, 55 (39.0%) received CCRT and 86 (61.0%) received chemotherapy alone. The outcomes and adverse events (AEs) were compared between the two groups. Results The baseline clinical characteristics of the two groups were similar. However, the CCRT group showed a significantly better primary tumor objective response rate (ORR) than that of the chemotherapy group (74.5% versus 45.3%, p = 0.001). The 1-year, 2-year, 3-year overall survival (OS) rates and median OS were 58.0% versus 43.0%, 25.5% versus 14.0%, 10.7% versus 4.7%, and 14 months versus 11 months for patients treated with CCRT or chemotherapy, respectively (p = 0.007). The 1-year and median progression-free survival (PFS) were 29.8% versus 14.9% and 8 months versus 6 months (p = 0.005). Multivariate analysis identified CCRT (p = 0.013) and solitary metastasis (p = 0.037) as independent factors for greater OS. The frequency of leucocytopenia (grade 3 or higher) was significantly higher in the CCRT group than in the chemotherapy-alone group (p = 0.040), whereas the rates of other AEs did not differ. Conclusions In this study, it is suggested that CCRT is more effective than chemotherapy alone for stage IV ESCC, yielding better primary responses and survival outcomes with tolerable side effects. |
| first_indexed | 2024-12-21T02:02:08Z |
| format | Article |
| id | doaj.art-123c4932834c48629cca4556ccd4ee10 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-12-21T02:02:08Z |
| publishDate | 2018-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-123c4932834c48629cca4556ccd4ee102022-12-21T19:19:37ZengBMCRadiation Oncology1748-717X2018-11-011311810.1186/s13014-018-1183-yOutcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled studyJiahua Lyu0Tao Li1Qifeng Wang2Fang Li3Peng Diao4Li Liu5Churong Li6Jinyi Lang7Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaDepartment of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of ChinaAbstract Background The purpose of this study is to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) versus chemotherapy alone for patients with stage IV esophageal squamous cell carcinoma (ESCC). Methods Eligible patients were retrospectively enrolled at the authors’s institution from January 2010 to October 2015. Of the 141 patients enrolled, 55 (39.0%) received CCRT and 86 (61.0%) received chemotherapy alone. The outcomes and adverse events (AEs) were compared between the two groups. Results The baseline clinical characteristics of the two groups were similar. However, the CCRT group showed a significantly better primary tumor objective response rate (ORR) than that of the chemotherapy group (74.5% versus 45.3%, p = 0.001). The 1-year, 2-year, 3-year overall survival (OS) rates and median OS were 58.0% versus 43.0%, 25.5% versus 14.0%, 10.7% versus 4.7%, and 14 months versus 11 months for patients treated with CCRT or chemotherapy, respectively (p = 0.007). The 1-year and median progression-free survival (PFS) were 29.8% versus 14.9% and 8 months versus 6 months (p = 0.005). Multivariate analysis identified CCRT (p = 0.013) and solitary metastasis (p = 0.037) as independent factors for greater OS. The frequency of leucocytopenia (grade 3 or higher) was significantly higher in the CCRT group than in the chemotherapy-alone group (p = 0.040), whereas the rates of other AEs did not differ. Conclusions In this study, it is suggested that CCRT is more effective than chemotherapy alone for stage IV ESCC, yielding better primary responses and survival outcomes with tolerable side effects.http://link.springer.com/article/10.1186/s13014-018-1183-yChemoradiotherapyEsophageal squamous cell carcinomaChemotherapyPrimary tumor response rateOverall survivalProgression-free survival |
| spellingShingle | Jiahua Lyu Tao Li Qifeng Wang Fang Li Peng Diao Li Liu Churong Li Jinyi Lang Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study Radiation Oncology Chemoradiotherapy Esophageal squamous cell carcinoma Chemotherapy Primary tumor response rate Overall survival Progression-free survival |
| title | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| title_full | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| title_fullStr | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| title_full_unstemmed | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| title_short | Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study |
| title_sort | outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage iv esophageal squamous cell carcinoma a retrospective controlled study |
| topic | Chemoradiotherapy Esophageal squamous cell carcinoma Chemotherapy Primary tumor response rate Overall survival Progression-free survival |
| url | http://link.springer.com/article/10.1186/s13014-018-1183-y |
| work_keys_str_mv | AT jiahualyu outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT taoli outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT qifengwang outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT fangli outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT pengdiao outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT liliu outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT churongli outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy AT jinyilang outcomesofconcurrentchemoradiotherapyversuschemotherapyaloneforstageivesophagealsquamouscellcarcinomaaretrospectivecontrolledstudy |